TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer.
SHANGHAI – Beigene Co. Ltd. has three candidates currently in phase I trials in Australia and has revealed the science and possible indications behind the cancer compounds: BGB-283, a second generation inhibitor of B-RAF; BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor, and BGB-3111, an inhibitor of Bruton tyrosine kinase (BTK).
Peptidream Inc., of Tokyo, inked a multitarget discovery and optimization collaboration with Merck & Co. Inc., of Kenilworth, N.J. Peptidream will use its Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck.
TOKYO – Two biotech companies from Japan are pooling complementary resources and products to tackle the rising incidence of dementia in a country with an aging population.
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman.
SHANGHAI – China may not be known for innovation, but Generon Corp. Ltd.'s founders decided 12 years ago they were not going to let that stop them from developing a potentially first-in-class biologic: F-652, a recombinant protein containing human interleukin 22 (IL-22).
HONG KONG – The findings of a Sino-U.S. study that links the aging process to the deterioration of heterochromatin could lead to methods of preventing and/or treating age-related diseases including cancer, diabetes and Alzheimer's disease, researchers reported in the May 1, 2015, issue of Science.
HONG KONG – Wuxi Pharmatech Inc. is building a $150 million biologics manufacturing facility for subsidiary Wuxi Biologics – the largest of its kind in China. When finished, the new facility will put the company in a different league, multiplying its production capacity and doubling its client base.
HONG KONG – A new patent law could help China step up enforcement and improve protections for intellectual property while giving biotech companies, both multinational and domestic, greater assurances that their products will be protected.
HONG KONG – A study by researchers at the Duke-National University of Singapore Graduate Medical School (Duke-NUS) has identified a new means by which brown adipose tissue is regulated in the body, which offers an attractive new target for the development of new obesity treatments.
RSS